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Abstract: 
 
(5Z)-7-Oxozeanol and related analogues were isolated and screened to explore their activity as 
TAK1 inhibitors. Seven analogues were synthesized and more than a score of natural products 
isolated that examined the role that different areas of the molecule contribute to TAK1 
inhibition. A novel nonaromatic difluoro-derivative was synthesized that had similar potency 
compared to the lead. This is the first example of a nonaromatic compound in this class to have 
TAK1 inhibition. Covalent docking for the isolated and synthesized analogues was carried out 
and found a strong correlation between the observed activities and the calculated binding. 
 
Keywords: (5Z)-7-Oxozeaenol | TAK1 | Selectfluor® | Covalent docking | Resorcylic acid 
lactone 
 
Article: 
 
1. Introduction 
 
Transforming growth factor-β-activated kinase 1 (TAK1) is a member of the serine/threonine 
mitogen-activated protein kinase kinase kinase (MAP3K) family.1 A wide range of extracellular 
stimuli, such as proinflammatory interleukins, activate the intracellular TAK1 via membrane-
bound receptors.2 Turning on of the upstream key signaling enzyme results in subsequent 
phosphorylation of specific MAP2Ks and MAPKs, which in turn activates a number of 
transcription factors including AP-1 and NF-κB.3 The aforementioned DNA-binding proteins are 
known to regulate inflammatory responses and apoptosis. Inhibition of upstream kinases such as 
MAP3Ks has an advantage over inhibiting downstream signaling molecules, mostly due to the 
former being more stimuli-specific.4 Indeed, it has been shown that inhibiting the TAK1/NF-κB 
signaling pathway, using either TAK1 inhibitors or via silencing its expression, promotes 
apoptosis in colon cancer,5 suppresses renal cell6 carcinoma survival,7 inhibits proliferation of 
LPS-induced human hepatocellular carcinoma,8 and reverses chemoresistance of pancreatic 
cancer.9 
 
 
Figure 1. Structures of isolated RALs from MSX 63935 (1–7) and a representative RAL from a 
different fungal strain (see Fig. S19 for additional isolated compounds). 
 
In 1978, Ellestad et al. reported the isolation of (5Z)-7-oxozeaenol (1) (Fig. 1), a β-resorcylic 
acid lactone (RAL), from an unidentified fungus.10 (5Z)-7-Oxozeaenol and its synthetic 
derivatives have received extensive attention for their biological activities.11 In 2003 it was found 
that 1 was a potent inhibitor of TAK1 with an IC50 of 8.1 nM.12 (5Z)-7-Oxozeaenol binds 
covalently to its target and, similar to almost all other kinase inhibitors,13 is a competitive ATP 
ligand that binds covalently to its target.12 This irreversible interaction was determined when the 
covalently-bound ligand was co-crystalized with TAK1.14 The interest in discovering and 
developing small molecule covalent inhibitors stems from the fact that these ligands may have 
increased selectivity for their targets and therefore the potential for less intense side effects, 
resulting from dose reduction of the candidate drug to achieve therapeutic efficacy.15 Selectivity 
of covalent inhibitors between kinases is difficult to achieve because the target is the ATP-
binding pocket, which is highly conserved.16 However, the selectivity profile often improves 
when moving from biochemical to cell-based kinase screening. There was a promising degree of 
selectivity for (5Z)-7-oxozeaenol since a 1 μM concentration exhibited at least 50% inhibition for 
only 12 of the 85 kinases tested by Wu et al. and in cell lines the macrolide inhibitor was even 
more selective for TAK1 inhibition.14 Due to the selective and potent activity with this 
medicinally important receptor, it was decided that (5Z)-7-oxozeaenol was worth further 
analysis. Filamentous fungus MSX 63935 is a prolific producer of (5Z)-7-oxozeaenol, 
reproducibly biosynthesizing over 800 mg per a single solid-based culture grown in a 2.8 L 
Fernbach flask.17 Six structurally related analogues of 1 were concomitantly isolated from this 
fungus (Fig. 1, 2–7) and 16 compounds from other strains (8 and S1–S15; see SI for full listing 
of structures).18 Seven additional compounds were also produced by semisynthesis using (5Z)-7-
oxozeaenol as the starting material (Scheme 1). All 30 compounds were analyzed for their 
inhibitory activity with TAK1. Covalent docking of the isolated and synthesized analogues was 
carried out to correlate, at a molecular level, structural changes with variations in inhibitory 
activity. These data are herein presented to establish structure–activity relationships for (5Z)-7-
oxozeaenol’s TAK1 activity. 
 
 
Scheme 1. Synthesis of compounds 9–16. 
 
2. Results and discussion 
 
2.1. Isolation of (5Z)-7-oxozeaenol (1) and related secondary metabolites 
 
The lead compound in this study, (5Z)-7-oxozeaenol 1, and six related analogues (Fig. 1) were 
isolated from solid-phase cultures of MSX 63935 as previously described in detail.17 The 
decision of choosing 1 as the lead for further diversification was primarily due to the greater 
potency in inhibiting NF-κB (11 nM).17 Fortuitously, the relative amount of cis-enone 1 was 
much higher in the extract compared to all other metabolites.17 In addition to the seven 
compounds from MSX 63935, 14 structurally related compounds were isolated from natural 
sources as previously described.16 
 
2.2. Synthesis of (5Z)-7-oxozeaenol analogues 
 
The rationale for analogue design was to explore key areas of the pharmacophore of (5Z)-7-
oxozeaenol. The free phenol was the first appealing position to synthetically diversify. The main 
reason for methylating the phenol was to verify the prior hypothesis that the phenol hydrogen 
bonds to the carbonyl of nearby residue Pro160.14 The use of diazomethane19 or iodomethane 
with sodium hydride20 did not result in the methylation of the hydroxy at carbon 17, as indicated 
by 1H NMR spectroscopy. Instead, macrolactone 1either decomposed or was unreactive under 
those conditions. The phenolic hydrogen is strongly hydrogen bonded to the nearby ester 
carbonyl oxygen, as can be inferred from the sharp singlet at 12 ppm in 1H NMR spectrum of 1. 
The use of potassium carbonate21 or tetrabutylammonium hydroxide22 in DMF produced a 
reaction, but only elimination instead of substitution (Scheme 1). Dienoates 9 and 10 suggest that 
the strong bases deprotonated one of the hydrogens on carbon 3 and this led to elimination of the 
ester attached to carbon 3. Under these more forcing conditions, the phenol was found to react 
with excess iodomethane. The stereochemical configurations of compounds 9 and 10 were 
assigned as (3E,5Z) based on the coupling constants between the protons at C3/C4 and C5/C6 
(i.e., 13.8 Hz and 11.5 Hz, respectively). Although dienoate 9 could be characterized, it was not 
sufficiently stable to be examined for biological activity. 
 
There has been an increased interest in introducing fluorine atoms into drug candidates for the 
enhanced pharmacokinetics and pharmacodynamics that this atom provides. For example, more 
than 25% of marketed drugs have at least one fluorine atom in their structures.23 The small size 
and large electronegativity of this heteroatom often leads to an increase in drug potency and half-
life due to decreased metabolism. In light of these advantages, fluorination was attempted. The 
reagent of choice for this reaction was the electrophilic Selectfluor®, which usually has high 
levels of reactivity and selectivity.24 Surprisingly, the product obtained was a result of 
difluorination at carbon 14 (Scheme 1). Attempts to synthesize the monofluorinated compound 
led only to reduced yields of the difluorinated product. Although this difluoro compound (11) 
was unexpected, it is highly important since it tests hydrogen bond donation at the phenolic 
position and is the first nonaromatic structure in the class of molecules to be tested for binding to 
TAK1. 
 
In a separate attempt to introduce fluorine into the molecule, trifluoromethylation was carried 
out. Unexpectedly, the major product obtained when using sodium trifluoromethane sulfinate, 
copper(II) trifluoromethane sulfonate and hydrogen peroxide25 resulted in the formation of 
bromide 12 (Scheme 1). It was surmised that trace impurities of a bromine-containing 
contaminant, as suggested by mass analysis of sodium trifluoromethane sulfinate, were the 
source of reactive bromine. Fortunately, when arene 1 was treated with NBS, bromination at 
either or at both positions occurred to provide for more reproducible bromination conditions.26 
 
To investigate the importance of the free hydroxyl groups at carbons 8 and 9 for activity, 
acetonide formation was targeted. The use of acetone with dimethylsulfoxide27 was not 
successful to prepare the target product, however, dimethoxypropane with catalytic amounts of 
p-toluenesulfonic acid was successful if only 0.08 equiv10 of the acid were used. Larger amounts 
of acid28 in CH2Cl2 activated the carbonyl at carbon 7 and facilitated intramolecular conjugate 
addition of the oxygen at carbon 9 to give pyranone 15 (Scheme 1). 
 
2.3. Analysis of TAK1 inhibition 
 
The synthesized analogues 10–16, isolated RALs 1–8 (Fig. 1), and RALs S1–S15 (Fig. S19) 
were evaluated for their in vitro TAK1 inhibitory activities (Table 1). Compound 9 was not 
tested due to the short term stability as indicated by the sub 90% purity detected by UPLC 
following prep HPLC purification. It was verified that the Michael acceptor was, as expected, a 
crucial part for the inhibitory activity of this group of compounds. Loss of this functionality, 
which is involved in covalent bond formation, whether through reduction of the double bond or 
reduction of the carbonyl, lead to loss of activity as seen with zeaenol (3), LL-Z164-1 (7), 
dihydrohypothemycin (5), pyranone 15, and compounds S1–S15. Not only was the enone 
presence crucial to the pharmacophore structure, the position matters also, since shifting the 
enone from Δ5,7 to Δ9,11, as in greensborone C (8), diminished activity. Additionally, 
isomerization of the enone double bond from a Z to an E configuration significantly reduced 
activity. This effect can be seen comparing two different pairs of isomers, namely; (5Z)-7-
oxozeaenol (1) versus (5E)-7-oxozeaenol (2) and hypothemycin (4) versus aigialomycin A (6). 
 
Table 1. Docking scores of enone-containing natural and semisynthetic RALs following prime 
minimization 
Structure Docking score IC50a (μM) 
1 −12.9 0.011 
4 −12.0 0.033 
11 −12.9 0.077 
13 −10.2 0.36 
16 −10.8 0.38 
6 N/Ab 0.99 
2 −11.5 1.3 
12 −10.0 2.6 
7 N/Ab 2.6 
14 −6.8 8.9 
3 N/Ab 10 
5 N/Ab >30 
8 −8.4 >30 
10 −6.4 >30 
15 N/Ab >30 
a See Table S1 for the 95% confidence intervals. 
b Compounds were not docked due to a lack of a suitable Michael acceptor functionality. 
 
By comparing 1 and 4, it can be inferred that epoxidation of the double bond on carbons 11 and 
12 does not change the inhibitory activity. As mentioned by Chen et al.14, the hydroxy group 
located at carbon 9 binds to the enzyme via formation of a hydrogen bond with the backbone 
carbonyl of Pro160. As expected, blocking this interaction, as seen in acetonide 16, reduced the 
activity by more than 30 fold. The inability of compound 10 to inhibit TAK1 indicated that the 
macrocycle was important for activity, probably due to the rigidity it provides to correctly 
position the Michael acceptor close to the nucleophilic cysteine residue. The only derivatized 
analogue that was found to be statistically equipotent to 1was difluoro (5Z)-7-oxozeaenol 11. 
The relative potency of 11 indicated that the aromatic ring was not crucial for binding. This 
observation with TAK1 and related structures is unprecedented. 
 
The crystal structure of 1 bound to TAK1 indicated that there was insufficient space to 
accommodate a bromine atom on carbon 16. Thus, as expected, the 16-bromo analogue (12) was 
significantly less active. As for substituting position 14 with bromine; the aforementioned 
analogue 13 showed better activity than 12, yet was 5 times less active than the difluoro 
derivative 11, despite the fact that the radius of bromine atom is almost equivalent to two 
fluorine atoms. A possible explanation of such difference between 11 and 13 is attributed to the 
observation, shown in the covalent docking outputs of the two ligands, that the two fluorines 
were oriented deeper into the binding pocket, while the bromine protrudes further out of the 
binding pocket, creating unfavorable interactions with residues 42, 43 and 111. Alternatively, the 
electronic nature of the six-membered ring is also significantly altered between the difluoro 
compound (11) and the 14-bromo compound (13), which could also impact binding. The added 
clashes of having bromine at positions 14 and 16 rendered dibromo analogue 14 the least active. 
 
2.4. Covalent docking 
 
Prior to docking, ligands having the Michael acceptor moiety were examined using Spartan 
(Wavefunction, Inc.).29 Compounds without the Michael acceptor were not suitable for this 
covalent docking study since the cysteine needs to covalently add into the compound. The 
structures of those ligands were first subjected to conformational searches using semiempirical 
molecular mechanics. The resulting conformers, ranging from 100 to 600, were further 
optimized using Hartree–Fock implementing the 6-31G∗ basis set. The theoretical global 
minimum energy conformation was chosen to be docked into the crystal structure. 
 
The prepared ligands were docked using the Chen and co-workers14 reported crystal structure 
(PDB 4GS6). The crystal structure was first prepared using protein preparation wizard (Maestro), 
and the prepared ligands were docked using covalent docking implemented in Maestro. 
 
To validate the accuracy of the calculations performed in regards to our work, (5Z)-7-
oxozeaenol 1 was the first ligand docked and the output was superimposed to the crystal 
structure having an RMSD of 0.0984 Å (Fig. 2). The geometry shown in the crystal structure was 
that of sp2 carbons at carbons 5 and 6. It is assumed that the geometry of carbons 5 and 6 in the 
crystal structure were incorrectly assigned, since both of these carbons should be sp3 hybridized 
after addition of the cysteine. After overlaying the two possible options (R and S at carbon 5), it 
was determined that the 5S-diastereomer was a better fit, especially with the cysteine in the 
crystal structure. We therefore hypothesize that the crystal structure should actually be 5S. 
 
 
Figure 2. (A) Superimposed covalent docking output pose for the 5R (blue) and 5S (green) 
diastereomers with the cocrystalized (5Z)-7-oxozeaenol (gray). Parts of the enzyme’s residues 
(R44, G45, A46, Y106, A107 and E108), in the binding pocket, were deleted for clarification; 
(B) −90° rotation of (A) around Y axis. Deleted enzyme residues are D175, F176 and G177. 
 
Similar to the parent ligand, semisynthesized and isolated RALs bearing an enone were also 
docked covalently. The best docking orientations, as judged by the docking score, were further 
subjected to protein refinement using prime implemented in Maestro followed by covalent 
docking of the minimization outputs (Table 1). Distinct gaps were observed between compounds 
having inhibitory concentrations in the nM range, low μM range, and the inactive compounds. 
Analogues having low nM inhibitory concentration had docking scores of −12 to 
−12.9 Kcal/mol. A range of −10 to −11.5 Kcal/mol was representative of analogues having 0.4–
2.6 μM range of activities. Inactive compounds had considerably worse docking scores 
compared with the active compounds. 
 
3. Conclusion 
 
(5Z)-7-Oxozeaenol (1) and twenty-nine diverse analogues were isolated and synthesized to 
examine their potential medicinal value as TAK1 inhibitors. It was determined that the presence, 
position, and stereochemical configuration of the Michael acceptor was of importance, along 
with the presence of the macrolactone. A nonaromatic difluorocyclohexenone was found to have 
only a moderate reduction in activity, which is of significance since all prior structures examined 
that are related to this scaffold had the aromatic ring. Bromination of two positions of the 
aromatic ring was explored and it was determined that a bromine in the 16 position was highly 
detrimental, whereas a bromine in the 14 position was tolerated. A covalent docking model, 
based on the previously reported crystal structure,12 was utilized to rationalize the activities. The 
modeling was also explored to formulate a hypothesis about the correct diastereomer of the 
covalently bound ligand since the reported crystal structure is lacking this stereochemical 
information. Future studies into metabolic stability and selectivity of these analogues are 
underway. 
 
4. Experimental 
 
4.1. General experimental procedures 
 
All solvents and reagents were obtained from commercial sources and were used as received. 
The purification of 1 from solid state cultures of MSX 63935 was performed as has been 
previously described.17 Unless otherwise stated, all reactions were carried out under an 
atmosphere of dry nitrogen in dried glassware. Indicated reaction temperatures refer to those of 
the reaction bath, while room temperature (rt) is noted as 25 °C. Analytical thin layer 
chromatography (TLC) was performed on silica gel 60 F254 precoated plates (0.25 mm) from 
Merck. Visualization was accomplished by irradiation under a 254 nm UV lamp. Silicycle silica 
gel 230–400 (particle size 40–63 μm) mesh was used for all flash column chromatography. The 
crude extract and reaction products were purified by reverse phase chromatography, which was 
performed using a Varian purification system employing a Phenomenex Gemini-NX, (5 μm, 
C18, 110A, AX. 250 × 21.20 mm). The mobile phase was a mixture of acetonitrile and H2O 
containing 0.1% formic acid. 1H NMR spectra were recorded on a JEOL ECA 500 MHz 
spectrometer or a JEOL ECS 400 MHz spectrometer in the solvent indicated. All 1H NMR 
experiments are reported in δ units, parts per million (ppm) downfield of TMS, and were 
measured relative to the signals for chloroform (7.26 ppm), methanol (3.31 ppm), acetone 
(2.05 ppm) and dimethylsulfoxide (2.50 ppm). All 13C NMR spectra were reported in ppm 
relative to the signals for chloroform (77.0 ppm), methanol (49.0 ppm), acetone (29.8 ppm) and 
dimethylsulfoxide (39.5 ppm) with 1H decoupled observation. Data for 1H NMR are reported as 
follows: chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, 
quint = quintet, sext = sextet, sept = septet, m = multiplet, bs = broad singlet), integration and 
coupling constant (Hz), whereas 13C NMR analyses were reported in terms of chemical shift. 
High resolution mass spectra (HRMS) were performed on a Thermo Fisher Scientific 
UPLC/LTQ Orbitrap XL system. 
 
4.2. Synthesis of (5Z)-7-oxozeaenol analogues 
 
4.2.1. Methyl 2-((1E,4S,5S,7Z,9Z)-4,5-dihydroxy-6-oxoundeca-1,7,9-trien-1-yl)-6-hydroxy-4-
methoxybenzoate (9)21 
 
Potassium carbonate (38 mg, 0.28 mmol) was added to a solution of (5Z)-7-oxozeaenol (50 mg, 
0.14 mmol) in DMF (2 mL) and stirred for an hour at rt. Iodomethane (10 μL, 0.16 mmol) was 
then added and the mixture stirred for 4 h at rt. It was diluted with water (20 mL) and acidified 
with 1 M HCl to pH of 2, followed by extraction with CHCl3(20 mL × 3). The combined organic 
layers were dried using anhydrous sodium sulfate and the solvent evaporated. The residue was 
purified by preparative HPLC using a Phenomenex Gemini-NX column C18 (250 × 21.20 mm, 
110 A, 5 μm spherical particle size). The column was perfused at a flow rate of 21.24 mL/min 
with 70% of (water, 0.1% FA) and 30% of (CH3CN) over 80 min. The compound eluted at 
∼70 min. Yield (6.6 mg, 13%). 1H NMR (500 MHz, CDCl3) δ 11.56 (s, 1H; 17-OH), 7.43 
(ddq, Jq = 1.2 Hz, Jd = 11.5, 14.9 Hz, 1H; 4-H), 6.98 (d, J = 15.5 Hz, 1H; 12-H), 6.57 
(dd, J = 11.2, 11.5 Hz, 1H; 5-H), 6.41 (d, J = 2.9 Hz, 1H; 14-H), 6.37 (d, J = 2.9 Hz, 1H; 16-H), 
6.25 (dq, Jd = 14.9 Hz, Jq = 6.9 Hz, 1H; 3-H), 6.08 (d, J = 11.5 Hz, 1H; 6-H), 5.84 
(dt, Jd = 15.5 Hz, Jt = 7.5 Hz, 1H; 11-H), 4.37 (bs, 1H; 8-H), 3.95 (dt, Jt = 4.6 Hz, Jd = 8.0 Hz, 
1H; 9-H), 3.91 (s, 3H; 21-H), 3.80 (s, 3H; 20-H), 2.33–2.40 (m, 2H; 10-H), 1.90 (d, J = 6.9 Hz, 
3H; 19-H). 13C NMR (125 MHz, CDCl3) δ 198.9, 171.5, 164.9, 164.2, 146.7, 145.2, 142.8, 
135.2, 129.3, 127.5, 117.9, 108.5, 103.7, 100.0, 79.4, 72.2, 55.5, 52.3, 35.7, 19.0. HRMS 
(ESI, m/z): Calculated for C20H25O7 [M+H]+ 377.1595; found 377.1589 (1.5 ppm). 
 
4.2.2. Methyl 2-((1E,4S,5S,7Z,9Z)-4,5-dihydroxy-6-oxoundeca-1,7,9-trien-1-yl)-4,6-
dimethoxybenzoate (10)21 
 
Same as procedure described for synthesis of compound 9. Compound 10 eluted at ∼46 min. 
UPLC was used to evaluate the purity using a gradient solvent system that initiated with 20:80 
CH3CN−H2O to 100% CH3CN over 4.5 min (>97% pure; Fig. S1, SI). Yield (18.0 mg, 34%). 1H 
NMR (500 MHz, CDCl3) δ 7.43 (ddq, Jq = 1.2 Hz, Jd = 11.5, 14.9 Hz, 1H; 4-H), 6.57 
(d, J = 11.5 Hz, 1H; 5-H), 6.54 (d, J = 2.3 Hz, 1H; 14-H), 6.40 (d, J = 15.8 Hz, 1H; 12-H), 6.34 
(d, J = 2.3 Hz, 1H; 16-H), 6.24 (dq, Jd = 14.9 Hz, Jq = 6.9 Hz, 1H; 3-H), 6.13 
(dt, Jd = 15.8 Hz, Jt = 7.5 Hz, 1H; 11-H), 6.04 (d, J = 11.5 Hz, 1H; 6-H), 4.35 (d, J = 4.0 Hz, 1H; 
8-H), 3.96–3.92 (m, 1H; 9-H), 3.87 (s, 3H; 21-H), 3.80 (s, 3H; 22-H), 3.78 (s, 3H; 20-H), 2.42–
2.35 (m, 1H; 10-H), 2.26 (ddd, J = 4.0, 7.4, 14.3 Hz, 1H; 10-H), 1.89 (d, J = 6.9 Hz, 3H; 19-
H). 13C NMR (125 MHz, CDCl3) δ 198.8, 168.7, 161.6, 158.2, 146.9, 145.2, 137.8, 130.5, 129.4, 
129.3, 117.9, 115.3, 101.8, 97.9, 79.4, 72.4, 56.1, 55.5, 52.5, 35.9, 19.1. HRMS: (ESI, m/z): 
Calculated for C21H27O7 [M+H]+ 391.1751; found 391.1745 (1.6 ppm). 
 
4.2.3. (3S,5Z,8S,9S,11E)-13,13-Difluoro-8,9-dihydroxy-14-methoxy-3-methyl-3,4,9,10-
tetrahydro-1H benzo[c][1]oxacyclotetradecine-1,7,16(8H,13H)-trione (11)24 
 
Selectfluor® (180 mg, 0.50 mmol) was added to a solution of (5Z)-7-oxozeaenol (30 mg, 
0.083 mmol) in CH3CN (3 mL) and the mixture stirred for 3 h at room temperature. The solvent 
was evaporated and the residue was diluted with ethyl acetate (5 mL) and washed with water 
(5 mL). The organic layer was dried using anhydrous sodium sulfate, filtered and the solvent 
evaporated. The residue was purified by preparative HPLC using a Phenomenex Gemini-NX 
column C18 (250 × 21.20 mm, 110 A, 5 μm spherical particle size). The column was perfused at 
a flow rate of 21.24 mL/min with 60% (water, 0.1% TFA), and 40% of (MeOH) over 40 min. 
The compound eluted at ∼30 min. UPLC was employed to evaluate the purity using a gradient 
solvent system that initiated with 20:80 CH3CN−H2O to 100% CH3CN over 4.5 min (>97% pure 
based on the ELSD detector; Fig. S2, SI). Yield (27 mg, 14%). 1H NMR (500 MHz, 
CDCl3) δ 6.63 (dt, Jd = 11.5 Hz, Jt = 4.0 Hz, 1H; 5-H), 6.38–6.27 (m, 1H; 11-H), 6.31 
(d, J = 11.5 Hz, 1H; 6-H), 6.07 (d, J = 15.5 Hz, 1H; 12-H), 5.58 (t, J = 2.3 Hz, 1H; 16-H), 5.43 
(ddq, Jq = 6.3 Hz, Jd = 1.2, 10.3 Hz, 1H; 3-H), 4.47 (bs, 1H; 8-H), 4.13–4.11 (m, 1H; 9-H), 3.85 
(s, 3H; 20-H), 3.86–3.85 (m, 1H; 3-H), 2.57 (ddd, J = 6.9, 8.0, 15.5 Hz, 1H; 10-H), 2.46 (d, 
16.0 Hz, 1H; 4-H), 2.37 (dd, J = 15.5, 5.2 Hz, 1H; 10-H), 1.41 (d, J = 6.3 Hz, 3H; 19-H). 13C 
NMR (125 MHz, CDCl3) δ 198.3, 181.4, 164.2, 163.1 (t, J = 24.0 Hz, 1C; 15-C), 150.4, 140.2, 
138.3 (t, J = 25.0 Hz, 1C; 13-C), 130.3 (t, J = 5.8 Hz, 1C; 18-C), 123.1, 122.7, 108.9 
(t, J = 241.5 Hz, 1C; 14-C), 102.3 (t, J = 3.8 Hz, 1C; 16-C), 80.7, 73.8, 72.6, 57.0, 38.1, 37.2, 
21.4. HRMS (ESI, m/z): Calculated for C19H21F2O7 [M+H]+ 399.1250; found 399.1242 
(2.0 ppm). 
 
4.2.4. (3S,5Z,8S,9S,11E)-15-Bromo-8,9,16-trihydroxy-14-methoxy-3-methyl-3,4,9,10-
tetrahydro-1H-benzo[c][1]oxacyclotetradecine-1,7(8H)-dione (12)26 
 
N-Bromosuccinimide (7.4 mg, 0.041 mmol) was added to a solution of (5Z)-7-oxozeaenol 
(15 mg, 0.041 mmol) in CHCl3 (1 mL) and the mixture stirred for 4 h at room temperature. 
CHCl3 (4 mL) was added to the mixture and it was washed with water (5 mL). The organic layer 
was dried using anhydrous sodium sulfate, filtered and the solvent evaporated. The solvent was 
evaporated and the residue was purified by preparative HPLC using a Phenomenex Gemini-NX 
column C18 (250 × 21.20 mm, 110 A, 5 μm spherical particle size). The column was perfused at 
a flow rate of 21.24 mL/min with a linear gradient from 40% (CH3CN–H2O) to 50% over 
15 min. The compound eluted at 18.5 min. UPLC was used to evaluate the purity using a 
gradient solvent system that initiated with 20:80 CH3CN−H2O to 100% CH3CN over 4.5 min 
(>97% pure; Fig. S1, SI). Yield (1.76 mg, 14%). 1H NMR (500 MHz, CDCl3) δ 12.79 (s, 1H; 17-
OH), 6.88 (d, J = 15.3 Hz, 1H; 12-H), 6.42 (s, 1H; 14-H), 6.34 (dd, J = 11.5, 3 Hz, 1H; 6-H), 
6.22 (ddd, J = 2.3, 3.0, 11.5 Hz, 1H; 5-H), 6.03 (ddd, J = 15.3, 10.7, 4.6 Hz, 1H; 11-H), 5.26 
(ddq, Jd = 1.5, 8.5 Hz, Jq = 6.1 Hz, 1H; 3-H), 4.53 (dd, J = 2.3, 5.4 Hz, 1H; 8-H), 4.00 (bs, 1H; 9-
H), 3.95 (s, 3H; 20-H), 3.57 (ddd, J = 5.4, 10.7, 11.5 Hz, 1H; 4-H), 2.53 (dd, J = 2.3, 17.6 Hz, 
1H; 4-H), 2.23–2.11 (m, 2H; 10-H), 1.48 (d, J = 6.1 Hz, 3H; 19-H). 13C NMR (100 MHz, 
CDCl3) δ 199.0, 171.1, 161.4, 160.4, 147.6, 142.3, 132.9, 131.1, 125.3, 104.8, 103.7, 99.1, 80.9, 
74.6, 73.6, 56.5, 37.5, 37.1, 20.8. HRMS (ESI, m/z): Calculated for 
C19H2279BrO7 [M+H]+ 441.0543; found 441.0546 (0.6 ppm), Calculated for 
C19H2281BrO7 [M+H]+ 443.0523; found 443.0521 (0.4 ppm). 
 
4.2.5. (3S,5Z,8S,9S,11E)-13-Bromo-8,9,16-trihydroxy-14-methoxy-3-methyl-3,4,9,10-
tetrahydro-1H-benzo[c][1]oxacyclotetradecine-1,7(8H)-dione26 (13) 
 
Same as procedure described for synthesis of compound 12. Compound 13 eluted at 14.5 min. 
UPLC was used to evaluate the purity using a gradient solvent system that initiated with 20:80 
CH3CN−H2O to 100% CH3CN over 4.5 min (>97% pure; Fig. S1, SI). Yield (6.4 mg, 52%). 1H 
NMR (500 MHz, CDCl3) δ 12.12 (s, 1H; 17-OH), 6.43 (s, 1H; 16-H), 6.39 (dd, J = 15.3, 2 Hz, 
1H; 12-H), 6.31 (dd, J = 11.5, 2.9 Hz, 1H; 6-H), 6.18 (dt, Jd = 2.9 Hz, Jt = 10.9 Hz, 1H; 5-H), 
5.72 (ddd, J = 3.4, 10.3, 16.0 Hz, 1H; 11-H), 5.40 (ddq, Jd = 1.7, 8.5 Hz, Jq = 6.1 Hz, 1H; 3-H), 
4.55 (bs, 1H; 8-H), 3.95 (bs, 1H; 9-H), 3.89 (s, 3H; 20-H), 3.74 (d, J = 4.0 Hz, 1H; 8-OH), 3.35 
(ddd, J = 10.9, 11.5, 17.2 Hz, 1H; 4-H), 2.51 (dd, J = 2.3, 17.2 Hz, 1H; 4-H), 2.33 (ddd, J = 2.3, 
4.3, 16.6 Hz, 1H; 10-H), 2.10 (ddd, J = 2.9, 10.3, 16.6 Hz, 1H; 10-H), 1.46 (d, J = 6.1 Hz, 3H; 
19-H). 13C NMR (125 MHz, CDCl3) δ 199.4, 170.9, 164.4, 161.1, 146.6, 142.2, 133.9, 129.6, 
125.6, 105.8, 105.4, 99.5, 81.0, 73.8, 73.1, 56.7, 37.0, 36.8, 21.0. HRMS (ESI, m/z): Calculated 
for C19H2279BrO7[M+H]+ 441.0543; found 441.0546 (0.6 ppm), Calculated for 
C19H2281BrO7 [M+H]+443.0523; found 443.0522 (0.2 ppm). 
 
4.2.6. (3S,5Z,8S,9S,11E)-13,15-Dibromo-8,9,16-trihydroxy-14methoxy-3-methyl-3,4,9,10-
tetrahydro-1H-benzo[c][1]oxacyclotetradecine-1,7(8H)-dione (14)26 
 
Same as procedure described for synthesis of compound 12. Compound 14 eluted at 21 min. 
UPLC was used to evaluate the purity using a gradient solvent system that initiated with 20:80 
CH3CN−H2O to 100% CH3CN over 4.5 min (>97% pure; Fig. S1, SI). Yield (1.4 mg, 10%). 1H 
NMR (500 MHz, CDCl3) δ 12.46 (s, 1H; 17-OH), 6.37 (d, J = 16.0 Hz, 1H; 12-H), 6.32 
(dd, J = 11.5, 2.9 Hz, 1H; 6-H), 6.20 (ddd, J = 2.9, 10.9, 11.5 Hz, 1H; 5-H), 5.72 (ddd, J = 3.4, 
10.3, 16.0 Hz, 1H; 11-H), 5.47 (ddq, Jq = 6.3, Jd = 1.7, 11.5 Hz, 1H; 3-H), 4.55 (dd, J = 5.2, 
2.3 Hz, 1H; 8-H), 3.95 (bs, 1H; 9-H), 3.90 (s, 3H; 20-H), 3.72 (d, J = 5.2 Hz, 1H; 8-OH), 3.40 
(ddd, J = 10.9, 11.5, 17.2 Hz, 1H; 4-H), 2.53 (ddd, J = 2.3, 2.9, 17.2 Hz, 1H; 4-H), 2.36–2.31 (m, 
2H; 10-H, 9-OH), 2.13 (ddd, J = 2.3, 10.3, 16.6 Hz, 1H; 10-H), 1.39 (d, J = 6.3 Hz, 3H; 19-
H). 13C NMR (100 MHz, CDCl3) δ 199.2, 170.5, 160.0, 159.6, 146.4, 141.3, 134.6, 129.1, 125.1, 
104.7, 103.6, 99.0, 80.9, 74.8, 73.0, 60.6, 37.0, 36.8, 20.8. HRMS (ESI, m/z): Calculated for 
C19H2179Br2O7 [M+H]+ 518.9648; found 518.9633 (3.0 ppm), Calculated for 
C19H2179Br81BrO7 [M+H]+ 520.9628; found 520.9613 (2.9 ppm), Calculated for 
C19H2181Br2O7 [M+H]+ 522.9608; found 522.9593 (2.8 ppm). 
 
4.2.7. (12S,13S,8S,E)-13,53-Dihydroxy-55-methoxy-8-methyl13,14,15,16-tetrahydro-12H-7-
oxa-1(2,6)-pyrana-5(1,2)benzenacyclononaphan-3-ene-14,6-dione (15)28 
 
p-Toluenesulfonic acid (0.5 mg, 0.003 mmol) was added to a solution of (5Z)-7-oxozeaenol 
(5.0 mg, 0.014 mmol) in CH2Cl2 (2 mL) and the mixture stirred overnight at room temperature. 
The reaction mixture was quenched with 10% aqueous NaHCO3 (2 mL), the organic layer dried 
using anhydrous sodium sulfate and the solvent evaporated. The residue was purified by 
preparative HPLC using a Phenomenex Gemini-NX column C18 (250 × 21.20 mm, 110 A, 5 μm 
spherical particle size). The column was perfused at a flow rate of 21.24 mL/min with solvent A 
(water, 0.1% TFA), and a linear gradient from 40% to 50% of solvent B (CH3CN) over 30 min. 
The compound eluted at 28.5 min. UPLC was used to evaluate the purity using a gradient solvent 
system that initiated with 20:80 CH3CN−H2O to 100% CH3CN over 4.5 min (>97% pure; Fig. 
S1, SI). Yield (1.8 mg, 35%). 1H NMR (400 MHz, CDCl3) δ 11.19 (s, 1H; 17-OH), 7.13 
(d, J = 16.0 Hz, 1H; 12-H), 6.36 (d, J = 2.8 Hz, 1H; 16-H), 6.33 (d, 2.8 Hz, 1H; 14-H), 5.83 
(ddd, J = 6.4, 6.9, 16.0 Hz, 1H; 11-H), 5.20–5.12 (m, 1H; 3-H), 4.68–4.63 (m, 1H; 5-H), 4.11 
(dd, J = 9.6, 4.1 Hz, 1H; 8-H), 3.85 (ddd, J = 2.8, 8.2, 10.1 Hz, 1H; 9-H), 3.80 (s, 3H; 20-H), 
3.55 (d, J = 4.1 Hz, 1H; 8-OH), 2.89 (dd, J = 15.1, 6.9 Hz, 1H; 6-H), 2.72 (dd, J = 7.0, 14.5 Hz, 
1H; 10-H), 2.48 (dd, J = 15.1, 3.7 Hz, 1H; 6-H), 2.44–2.38 (m, 1H; 10-H), 2.21 (ddd, J = 4.1, 
6.6, 8.2 Hz, 1H; 4-H), 1.56–1.54 (m, 1H; 4-H), 1.41 (d, J = 6.0 Hz, 3H; 19-H). 13C NMR 
(100 MHz, CDCl3) δ207.6, 171.2, 164.3, 164.1, 143.7, 135.7, 125.7, 107.5, 105.1, 99.8, 77.7, 
76.2, 73.6, 72.4, 55.5, 46.2, 37.2, 33.3, 21.7. HRMS (ESI, m/z): Calculated for 
C19H23O7 [M+H]+ 363.1438; found 363.1433 (1.5 ppm). 
 
4.2.8. (3aS,5Z,8S,15E,17aS)-11-Hydroxy-13-methoxy-2,2,8-trimethyl-7,8,17,17a-tetrahydro-4H-
benzo[c][1,3]dioxolo[4,5-h][1]oxacyclotetradecine-4,10(3aH)-dione (16)10 
 
p-Toluenesulfonic acid (2.0 mg, 0.012 mmol, 9 mol %) was added to a suspension of (5Z)-7-
oxozeaenol (50.0 mg, 0.138 mmol) in dimethoxypropane (20 mL) and the mixture stirred for an 
hour at room temperature. Dimethoxypropane was evaporated, the residue dissolved in 
CHCl3 (20 mL), and the reaction quenched with 10% aqueous NaHCO3(10 mL). The organic 
layer was dried over anhydrous magnesium sulfate and the solvent evaporated. The residue was 
purified by preparative HPLC using a Phenomenex Gemini-NX C18 column (250 × 21.20 mm, 
110 A, 5 μm spherical particle size). The column was perfused at a flow rate of 21.24 mL/min 
with (water, 0.1% TFA), and a linear gradient from 60% to 70% of (CH3CN) over 15 min. The 
compound eluted at 16.5 min. UPLC was used to establish purity using a gradient solvent system 
that initiated with 20:80 CH3CN/H2O to 100% CH3CN over 4.5 min (>97% pure; Fig. S1, SI). 
Not all signals were observed in the 1H and 13C NMR spectra due to the equilibration of distinct 
conformers. Definitive structural assignment was determined by the hydrolysis of the acetonide 
to regenerate (5Z)-7-oxozeaenol where 16 (2 mg, 0.005 mmol) was dissolved in MeOH and 1 
drop of HCl (1 M) was added. The formation of 1 was monitored using 1H NMR. Yield 
(23.6 mg, 43%). 1H NMR (500 MHz, CDCl3) δ 12.07 (s, 1H; 17-OH), 6.93 (d, J = 15.1 Hz, 1H; 
12-H), 6.36 (s, 2H; 14-H and 16-H), 5.73–5.67 (m, 1H; 11-H), 5.37 (bs, 1H; 3-H), 4.58–4.54 (m, 
2H; 8-H and 9-H), 3.79 (s, 3H; 20-H), 2.67–2.58 (m, 2H; 3-H), 1.57 (s, 3H; 21-H), 1.47 
(d, J = 6.4 Hz, 3H; 19-H). 1.38 (s, 3H; 22-H). 13C NMR (100 MHz, CDCl3) δ 196.5 (m, 7-C
O), 171.1, 165.6, 163.9, 146.3 (m; 5-C), 142.6, 133.6, 127.1 (m; 6-C), 126.6, 110.0, 108.9, 103.6, 
100.1, 81.7 (m; 8-C), 77.2, 72.9 (m; 3-C), 55.4, 35.8, 27.0, 25.2 (m; (CH3)2), 19.9 (m; 19-C). 
HRMS: (ESI, m/z): Calculated for C22H27O7 [M+H]+ 403.1751; found 403.1749 (0.6 ppm). 
 
4.3. Computational calculations and covalent docking 
 
All calculations were carried out using SPARTAN’08 for Linux. Initial conformational analyses 
were carried out on each ligand using a Monte-Carlo molecular mechanics conformational search 
using the RM1/semi-empirical force field at the ground state. All resulting conformations 
with Erel less than 10 kcal/mol, relative to the lowest-energy conformation, were then modeled 
using Hartree–Fock with the 6-31G∗ basis set in the gas phase. The resulting global minimum 
was exported to Maestro as mol.2 file and subjected to covalent docking. 
 
Prior to covalent docking, the crystal structure (PDB ID: 4GS6) was prepared using protein 
preparation wizard, implemented in Maestro, where hydrogens were added to all atoms and bond 
orders were assigned. The covalent linkage between the co-crystalized (5Z)-7-oxozeaenol TAK1 
enzyme was broken, the ligand deleted and the bare enzyme used as the binding protein for 
docking. Covalent docking, implemented in Glide, was used to evaluate the relative binding 
affinities of the various ligands tested. The reaction type chosen was Michael addition where 
amino acid Cysteine 174 was identified as the reactive reside. The grid box was determined as 
the centroid of residues Cysteine 174, valine 42 and alanine 46. Cysteine 174 was not chosen as 
the sole determinant of the grid box because it is impeded at the back of the binding pocket thus 
will not result in spanning the biding site efficiently. Many residue combinations were screened 
and the aforementioned collection was representative of a box holding all atoms of the co-
crystalized (5Z)-7-oxozeaenol in the original crystal structure. 
 
The initial covalent docking output with the highest score for each docked ligand was minimized 
using prime, implemented in Maestro. All atoms including those of the enzyme and the ligand 
were minimized using VSGB solvation model. The number of iterations implemented for the 
automatic method of minimization was 8 and steps per iterations were 200. The covalent linkage 
between the docked ligand and the enzyme was broken again and the minimized ligand was 
covalently docked in the minimized enzyme. 
 
4.4. TAK1 inhibition assays 
 
The assay was performed at BSP Bioscience Inc. (5Z)-7-oxozeaenol was used as a positive 
control. Detailed experimental procedures are provided in the Supporting information. 
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TAK1 Inhibition Assay Procedure 
 
 The assay was performed using Kinase‒Glo Plus luminescence kinase assay kit (Promega). It 
measures kinase activity by quantifying the amount of ATP remaining in solution following a kinase 
reaction. The luminescent signal from the assay is correlated with the amount of ATP present and is 
inversely correlated with the amount of kinase activity. Compounds were diluted in 10% DMSO and 5 µL 
of the dilution was added to a 50 µL reaction so that the final concentration of DMSO is 1% in all of 
reactions. The compounds were preincubated with the enzyme in a reaction mixture for 10 min at room 
temperature. The enzymatic reactions were initiated by adding ATP (20 µM at final) and conducted for 40 
min at 30 °C. The 50 µL reaction mixture contained 40 mM Tris, pH 7.4, 10 mM MgCl2, 0.1 mg/mL 
BSA, 1 mM DTT, 0.2 mg/mL MBP substrate, 20 µM ATP and Tak1‒TAB1. After the enzymatic 
reaction, 50 µL of Kinase‒Glo Plus Luminescence kinase assay solution (Promega) was added to each 
reaction, and the plate was incubated for 20 min at room temperature. Luminescence signal was measured 
using a BioTek Synergy 2 microplate reader. Tak1‒TAB1 activity assays were performed in duplicate at 
each concentration. The luminescence data were analyzed using the computer software, Graphpad Prism. 
The difference between luminescence intensities in the absence of Tak1‒TAB1 (Lut) and in the presence 
of Tak1‒TAB1 (Luc) was defined as 100% activity (Lut – Luc). Using luminescence signal (Lu) in the 
presence of the compound, % activity was calculated as: % activity = [(Lut ‒ Lu)/(Lut ‒ Luc)]×100%, 
where Lu= the luminescence intensity in the presence of the compound. The values of % activity versus a 
series of compound concentrations were then plotted using non‒linear regression analysis of Sigmoidal 
dose‒response curve generated with the equation Y=B+(T‒B)/1+10((LogEC50‒X)×Hill Slope), where Y 
= percent activity, B = minimum percent activity, T = maximum percent activity, X = logarithm of 
compound and Hill Slope = slope factor or Hill coefficient. The IC50 values were determined by the 
concentration causing a half‒maximal percent activity. 
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UPLC Chromatograms of Compounds 1, 10-16 
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Figure S1. UPLC chromatograms of compounds 1, 10-16 (λ 254 nm), demonstrating >96% purity. All 
data were acquired via an Acquity UPLC system with a Phenomenex Kinetex C18 (1.3 µm; 50 × 2.1 mm) 
column and a CH3CN/H2O gradient that increased linearly from 20 to 100% CH3CN over 1.2 min. 
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NMR Data for Compounds 9-16 
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Figure S2. 1H and 13C NMR spectra of compound 9 [500 MHz for 1H and 125 MHz for 13C, CDCl3] 
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Figure S3. Major COSY ( ) and HMBC (blue arrows) correlations of compound 9 
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Figure S4. 1H and 13C NMR spectra of compound 10 [500 MHz for 1H and 125 MHz for 13C, CDCl3] 
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Figure S5. Major COSY ( ) and HMBC (blue arrows) correlations of compound 10 
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Figure S6. 1H and 13C NMR spectra of compound 11 [500 MHz for 1H and 125 MHz for 13C, CDCl3] 
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Figure S7. 19F NMR spectra of compound 11 [375 MHz, CDCl3] 
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Figure S8. Major COSY ( ) and HMBC (blue arrows) correlations of compound 11 
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Figure S9. 1H and 13C NMR spectra of compound 12 [500 MHz for 1H and 125 MHz for 13C, CDCl3] 
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Figure S10. Major COSY ( ) and HMBC (blue arrows) correlations of compound 12  
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Figure S11. 1H and 13C NMR spectra of compound 13 [500 MHz for 1H and 125 MHz for 13C, CDCl3] 
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Figure S12. Major COSY ( ) and HMBC (blue arrows) correlations of compound 13 
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Figure S13. 1H and 13C NMR spectra of compound 14 [500 MHz for 1H and 125 MHz for 13C, CDCl3] 
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Figure S14. Major COSY ( ) and HMBC (blue arrows) correlations of compound 8 
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Figure S15. 1H and 13C NMR spectra of compound 15 [500 MHz for 1H and 125 MHz for 13C, CDCl3] 
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Figure S16. Major COSY ( ) and HMBC (blue arrows) correlations of compound 15 
S12 
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Figure S17. 1H and 13C NMR spectra of compound 16 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
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Figure S18. Major COSY ( ) correlations for compound 16 
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Figure of Additional Isolated Resorcylic Acid Lactones that were Inactive  
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Figure S19. Related resorcylic acid lactones that were isolated from fungi and found to not inhibit TAK1 
at 30 µM concentrations. 
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Table of TAK1 Inhibitions with Confidence Intervals 
 
Table S1. TAK1 IC50’s and Confidence intervals of tested natural and synthesized RALs 
 
Compounda Docking Score IC50 (µM) 95% Confidence Intervals 
1 -12.9 0.011 0.009-0.015 
4 -12.0 0.033 0.024-0.045 
11 -12.9 0.077 0.047-0.13 
13 -10.2 0.36 0.25-0.50 
16 -10.8 0.38 0.22-0.66 
6 N/A 0.99 0.66-1.4 
2 -11.5 1.3 0.93-1.8 
12 -10.0 2.6 2.2-3.2 
7 N/A 2.6 2.2-3.2 
14 -6.8 8.9 7.7-11 
3 N/A 10 8.2-12 
5 N/A >30 NA 
8 -8.4 >30 NA 
10 -6.4 >30 NA 
15 N/A >30 NA 
 
 
 
 
 
